MIMS complements
December 20, 2012
MIMS has announced a new
partnership with UnityHealth,
which will see an Australian
evidence-based Complementary V
Mainstream drug interaction
module hit the market, via the
company’s eMIMS product.
“For healthcare professionals, the
primary barrier to recommending
complementary medicines is safety
concerns around patients on
multiple prescription medications
or with complex health issues,”
MIMS said in a statement.
“The provision of good quality
educational materials was seen as
important to allow pharmacists to
assess levels of evidence for CMs
and educate them on their safe and
appropriate use,” MIMS added.
The interactions data base has
been researched by the Sydney
University School of Pharmacy, and
has been updated and expanded
regularly since its creation in 2002.
The data now delivers over 500
interaction modules via the
website, IMgateway.
“Because eMIMS is so resourcerich
and used widely by doctors and
pharmacists as well as a diverse
range of other healthcare
professionals we chose it as the
first MIMS product to carry this
module,” said Dinah Graham, MIMS.
“The IMgateway database within
eMIMS will enable GPs, pharmacists
and other health professionals to
retrieve evidence-based
information on clinically-significant
drug and herb interactions.
“Subscribers can search a
complementary medicine against a
prescription medicine (or vice-versa),
quickly obtain a recommendation
on whether the combination
should be avoided, or be alerted if
caution is required,” she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Dec 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Dec 12
